|
|
|
| home | genetic news | bioinformatics | biotechnology | literature | journals | ethics | positions | events | sitemap |
Aurora And Twilight For Tumors
|
Targeted approaches to cancer treatment are showing increasing signs of success as alternatives to traditional chemotherapy. In the March issue of Nature Medicine, Karen Miller and colleagues use one such drug, called VX-680, to suppress tumor growth.
VX-680 inhibits the enzymatic activity of Aurora kinases, proteins that have an important role in cell division. Because cancer cells divide rapidly, blocking Aurora kinases selectively targets those cells. The authors show that, in a mouse model of cancer, VX-680 inhibits the proliferation of cancer cells, resulting in slower tumor growth. If further studies confirm the results, VX-680 might be used to specifically target tumor cells and minimize the side effects and toxicity seen with other cancer therapies, the authors suggest. Author contact: Karen M. Miller Also available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser. Use the links below to share this article on the social bookmarking site of your choice. Read more about social bookmarking at Wikipedia - Social Bookmarking |
PrimerBank: a centralized database of primers for QPCR The NCBI BioSystems database: a centralized resource for biomolecular systems Phenomizer: a freely available tool for clinical genetics BioGPS: a centralized online resource for gene annotation Brain Adaptations to Sensory Loss Sequencing Small Chips A Stroke Against Stroke Inhibition Present in Absences Assessing Natural Memory Variant Associated with Alcoholic Liver Disease Parkinson's Gene Mutated in Cancer more news ... |
Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S. Zollmann.
7.0 © 1995-2010 HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint.